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Pulmonary Resection for Metastases from
Colorectal Cancer
Paul M. van Schaik, MD,* Ewout A. Kouwenhoven, MD, PhD,* Robert J. Bolhuis, MD,*
Bonne Biesma, MD, PhD,† and Koop Bosscha, MD, PhD*
Introduction: The lung is the most common extraabdominal site for
metastases from colorectal cancer. Patients with untreated metastatic
disease have a median survival of less than 10 months and a 5-year
survival of less than 5%. The purpose of this study was to evaluate
long-term survival in patients who underwent pulmonary resection
for metastases from colorectal cancer.
Methods: Between January 1990 and January 2005, 23 patients
underwent 29 operations for resection of lung metastases.
Results: Median age was 68 years (range: 46–80 years). Median
follow-up was 30 months (range: 12–149 months). The 2- and
5-year overall survival rates were 64 and 26%, respectively. Of the
23 patients, 16 patients had a solitary lesion, and seven patients had
multiple lesions. The 5-year survival rates were 23 and 33%,
respectively (not significant). The median disease-free interval
(DFI)—the interval between colon resection and the appearance of
lung metastases—was 43 months (1–168). Ten patients had DFIs
36 months, and 13 patients had DFIs 36 months. The 3-year
survival rates were 20 and 38%, respectively (not significant).
Recurrence of lung metastases was diagnosed in seven patients;
three patients underwent second resections. They are alive today,
with a median follow-up of 18 months. Patients who did not undergo
second resections had a median survival of 12 months.
Conclusions: Pulmonary resection for metastases from colorectal
cancer does produce longer survival, even in patients with multiple
lesions and recurrent metastases.
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Colorectal cancer is the second-most commonly diagnosedmalignancy in men and women in the Netherlands.
One of the most important predictors of survival in
patients with colorectal cancer is lymph node status. In most
countries, patients with curatively resected colorectal cancer
without nodal tumor involvement do not receive adjuvant
chemotherapy because studies have failed to demonstrate a
beneficial effect.
Nevertheless, more than 30% of these patients will
develop locoregional recurrence or distant metastases.1 The
lung is the most common extraabdominal site of metastases in
patients affected by cancer of the colon. Patients with un-
treated metastatic disease have a median survival of less than
10 months and a 5-year survival of less than 5%.2
Conventional treatment of stage IV colorectal carci-
noma in most patients is palliative. For a long time, fluoracil-
based chemotherapy has been considered the standard treat-
ment, but it seldom has produced long-term survival. Because
no effective chemotherapy regimen has been identified for
pulmonary metastases of colorectal origin, surgery is the only
potentially curative treatment.
Divis3 performed the first resection of a pulmonary
metastasis in 1927. Several retrospective studies since then
have shown that patients with pulmonary metastases benefit
from resection.
The published 5-year survival rates after pulmonary
metastasectomy of colorectal origin range from 21 to 62%.4–7
The purpose of this study was to evaluate postoperative
mortality, morbidity, and long-term survival in patients who
underwent pulmonary metastasectomy for metastases of colo-
rectal cancer.
PATIENTS AND METHODS
Between January 1990 and January 2005, 23 patients
underwent 29 operations for resection of lung metastases
from colorectal cancer in the Jeroen Bosch Hospital, the
Netherlands. Data were collected from the patient records,
both electronic and paper. Information was collected on the
clinical characteristics of the patients, operative reports, and
the reports of the pathologist. The following patient charac-
teristics and data were analyzed: age, gender, carcinoembry-
onic antigen (CEA) levels, primary site of the tumor, number
and type of pulmonary resections, completeness of resection,
second resection, disease-free interval (DFI), infiltration of
pulmonary or mediastinal lymph nodes, postoperative mor-
bidity, mortality, and long-term survival.
Selection criteria for resection were as follows: (1)
controlled primary tumor, (2) controlled or controllable ex-
trathoracic lesion, and (3) computed tomography scan dem-
onstrating that radical resection could be performed regard-
less of the number of lesions. Tumors in both lungs were not
considered a contraindication. Principally, wedge resection
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was the procedure of choice; if this was not possible, a
lobectomy or a pneumonectomy was performed.
Survival was estimated by the method of Kaplan and
Meier, using the date of the pulmonary resection as the
starting point. The influence of variables on survival was
analyzed using the log-rank test for discrete variables. Fol-
low-up was done routinely every 3 months, using CEA levels
in blood samples and computed tomography of the thorax/
abdomen on indication. Table 1 and 2.
RESULTS
The median age of patients at time of diagnosis of lung
metastases was 68 years (range: 46–80 years). Twelve pa-
tients were men and 11 patients were women.
In 12 patients, the primary origin of the tumor was the
colon, and in 11 patients, the primary origin was the rectum.
There were 15 wedge resections, 11 lobectomies, two bilo-
bectomies, and one pneumonectomy.
There were 20 patients with unilateral disease and three
patients with bilateral disease. The median number of metas-
tases per patient was one.
At operation, no mediastinal lymph node dissection
was done routinely.
Only “lymph node picking” was done if there were
pathological lymph nodes during surgery. This procedure was
performed in 11 of the 23 patients. The mean number of
lymph nodes was two. There were no patients with metasta-
ses in these lymph nodes, and all operations were radical.
None of the operated patients died after surgery.
Five patients developed postoperative complications
(17.9%). One patient had a postoperative hemorrhage after a
wedge resection, necessitating rethoracotomy; one patient
had a wound infection after a wedge resection (sternotomy);
one patient developed pneumonia after a lobectomy; one
patient developed an abscess of the superficial thorax wound
after a wedge resection; and one patient developed an empy-
ema after a bilobectomy.
Pulmonary Metastasectomy and Survival
Median follow-up for the whole group was 30 months
(range: 12–149 months). The 2-, 5-, and 10-year overall
survival rates were 64, 25, and 12%, respectively. The 2-, 5-,
and 10-year cancer-free disease survival rates were 52, 18,
and 5%, respectively (Figure 1).
Combined Liver/Lung versus Lung Metastases
and Survival
One of 23 patients underwent a hemihepatectomy for
liver metastases before lung surgery. Originally, this patient
underwent a right hemicolectomy for a Dukes B colon car-
cinoma. After 2 years, the patient developed liver metastases.
One year after the hemihepatectomy, he developed
metastases of the right lung, for which he underwent a
bilobectomy. Two years after the bilobectomy, the patient
developed recurrent lung metastases and bone metastases. He
died 6 years after the bilobectomy.
DFI and Survival
DFI was defined as the interval between colon resection
and the appearance of lung metastases. DFIs ranged from 1 to
168 months, and the median DFI was 43 months. Ten patients
had a median DFI 36 months, and 13 patients had DFIs
36 months. The 3-year survival rates were 20 and 38%,
respectively (p  0.32) (Figure 2).
Solitary versus Multiple Lung Metastases and
Survival
Of the 23 patients, 16 patients had a solitary lesion and
seven patients had multiple lesions. The 2-year overall sur-
TABLE 1. Survival Rates of 23 Patients Who Underwent
Pulmonary Resection
Survival Rates 2 yr (%) 5 yr (%)
Overall survival 64 25
Cancer-free disease survival 52 18
Disease-free interval 36 months 79 0
Disease-free interval 36 months 78 38
Solitary lesions 70 23
Multiple lesions 50 33
TABLE 2. Number of Lesions and Type of Surgery
No. of Patients
Type of lesions
Solitary lesions 16
Multiple lesions 7
Recurrence 7
Type of surgery
Wedge resection 15
Lobectomy 11
Bilobectomy 2
Pneumonectomy 1
FIGURE 1. Kaplan-Meier survival curve for 23 patients who
underwent pulmonary resection for metastases from colorec-
tal cancer. Black solid line, overall survival; black dotted line,
cancer-free disease survival.
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vival rates for these groups were 70 and 50%, respectively.
Five-year survival rates were 23 and 33%, respectively (p 
0.404) (Figure 3).
Nevertheless, after 6.5 years, survival was 23% for
solitary lesions and 0% for multiple lesions.
Recurrence of Lung Metastases and Survival
Seven patients (30.4%) had a recurrence of lung me-
tastases, for which three underwent second resections. The
other four patients did not undergo second resections, be-
cause of extrathoracic disease (two patients) or because of
deteriorating physical condition (two patients). The median
DFI for patients with recurrence was 11 months (range: 4–31
months).
All surgically treated patients with recurrent lung me-
tastases are alive today, with a median follow-up of 18
months. Patients who did not undergo second resections had
a median survival of 12 months (Figure 4).
CEA Levels and Lung Metastases
In 11 of the 23 patients (48%), CEA levels were
determined both before and after surgery. The median CEA
level before surgery was 3 (range: 1.2–94), and the median
CEA level after operation was 1.8 (range: 0.5–170).
DISCUSSION
Almost 30 to 40% of patients with colorectal carcinoma
develop metastases despite curative resection of the primary
tumor.1 Of these patients, about 10% will develop lung
metastases.8 In addition, the majority of patients have recur-
rent extrathoracic disease.
In the literature, treatment of lung metastases was
considered debatable for a long time. Nonsurgical treatment
is still of only limited benefit to the patients; patients with
untreated metastatic disease have a median survival of less
than 10 months and a 5-year survival of less than 5%.2
In a highly selected group of patients, surgical inter-
vention is the current therapy of choice; the reported 5-year
survival rates range from 21 to 62%.4–7 In a study from Lee
et al.,9 59 patients underwent curative resection for pulmo-
nary metastases of colorectal cancer. The 5-year overall
survival rate of all patients who received pulmonary resection
FIGURE 4. Kaplan-Meier survival curve for patients with
primary lung metastases versus recurrent lung metastases.
Black solid line, primary lung metastases; black dotted line,
recurrent lung metastases.
FIGURE 2. Kaplan-Meier survival curves according to the
disease-free interval. Black dotted line, DFI 36 months; black
solid line, DFI 36 months.
FIGURE 3. Kaplan-Meier survival curve for solitary lesions
versus multiple lesions. Black solid line, solitary lesion; black
dotted line, multiple lesions.
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was 50%. In a study from Yedibela et al.,10 159 patients with
pulmonary metastases from colorectal cancer underwent 180
thoracotomies. The 2- and 5-year survival rates after the first
thoracotomy were 64 and 37%, respectively.
In our population, the actuarial 5-year survival for the
23 patients who underwent pulmonary resections for colorec-
tal metastases was 25%, and the 5-year DFS was 18%. With
regard to extrathoracic disease, especially liver metastases,
almost no authors contraindicated pulmonary resection in
patients who had previously received liver metastasec-
tomy.11,12,23 In a study from Murata et al.,13 30 patients had
undergone resection of both hepatic and pulmonary metasta-
ses from colorectal cancer. Actuarial 3- and 5-year survival
rates were 49 and 44%, respectively. In a study from Shah et
al.,14 39 patients underwent both lung and liver resections for
metastatic colorectal cancer. The median DFI and overall
survival after initial metastasectomy were 20 and 87 months,
respectively.
In a study from Iizasa et al.,15 among patients with
pulmonary metastasectomy with sequential resection after
partial hepatectomy, the 5-year survival rate was 32% after
pulmonary resection and 67% after colorectal resection.
In our study, only one patient received pulmonary
resection after a hemihepatectomy; he died 6 years later.
Although a longer DFI seems to be a favorable prog-
nostic factor in our study, it was not a significant prognostic
factor; this is supported by other authors.11,12,16 Patients with
DFIs 36 months had a 3-year survival of 20%, and patients
with DFIs 36 months had a 3-year survival of 38%.
In a study from Yedibela et al.,10 a DFI 36 months
was a predictor of longer survival duration by univariate
analysis but not by multivariate analysis.
In a study from Vogelsang et al.,17 DFI 10 months
was identified as the most important prognostic factor in
patients with smaller metastases (3.75 cm), but not in the
whole study group. This might explain why DFI has not been
shown consistently to be a prognostic factor in previous
studies.
Nevertheless, in a study from Rena et al.6 and Roberts
et al.,18 patients with DFIs 36 months had significantly
better survival rates than patients with DFIs 36 months.6,18
Many authors have reported that patients with soli-
tary metastases had better prognoses than those affected by
multiple lesions.11,12,16 In a study from Iizasa et al.,15 the
number of pulmonary metastases was found to be a sig-
nificant predictor for survival in both univariate and mul-
tivariate analysis. In a study from Girard et al.,19 a limited
number (fewer than two) of pulmonary metastases was a
predictor of longer survival duration by univariate analy-
sis, but not with multivariate analysis. In a study from
Inoue et al.,20 the number of metastases was a considerable
prognostic factor. In our study, patients with a solitary
lesion had a 2-year survival of 70%, and patients with
multiple lesions had a 2-year survival of 50%. The differ-
ence, nevertheless, did not reach significance.
Recurrent pulmonary disease after pulmonary metasta-
sectomy is a crucial problem; indication for reoperation is
still controversial. McAfee et al.12 have reported a 5-year
survival rate of 30.2% for 19 patients who underwent second
thoracotomies.
In our small study, seven patients had recurrent
pulmonary disease (30.4%), and three patients underwent
second resections for their metastases. All three patients
are alive today, with a median follow-up of 18 months. In
the literature, survival of patients after a recurrent thora-
cotomy for pulmonary metastases is comparable with the
primary thoracotomy patients; thus, patients should be
offered surgery.
Our data support the results of McAfee et al. and
Kandioler et al.12,21
In our study, none of the 23 patients died after surgery.
Five patients developed complications.
In conclusion, we believe that pulmonary resection
for metastases of colorectal cancer does produce longer
survival, even in patients with multiple lesions and recur-
rent metastases. It is a safe procedure, with low mortality
and morbidity.
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